OI
MCID: OST005
MIFTS: 69

Osteogenesis Imperfecta (OI) malady

Categories: Genetic diseases, Rare diseases, Bone diseases, Fetal diseases, Oral diseases

Aliases & Classifications for Osteogenesis Imperfecta

About this section
Sources:
11Disease Ontology, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Osteogenesis Imperfecta:

Name: Osteogenesis Imperfecta 11 71 48 24 25 54 50 38 39 13 68
Brittle Bone Disease 11 48 24 25 54
Oi 48 24 25 54
Fragilitas Ossium 11 48 25
Osteopsathyrosis 11 48 54
Porak and Durante Disease 48 54
Lobstein Disease 48 54
Vrolik Disease 48 25
 
Osteogenesis Imperfecta, Recessive Perinatal Lethal 68
Osteogenesis Imperfecta, Dominant Perinatal Lethal 68
Osteogenesis Imperfecta Type 27
Lobstein's Syndrome 11
Glass Bone Disease 54
Lobstein's Disease 68
Vrolik's Disease 11

Characteristics:

Orphanet epidemiological data:

54
osteogenesis imperfecta:
Inheritance: Autosomal dominant,Autosomal recessive; Prevalence: 1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Finland),1-9/1000000 (Latin America),1-9/100000 (Ireland),1-9/100000 (United States),1-9/100000 (Sweden); Age of onset: All ages

Classifications:



External Ids:

Disease Ontology11 DOID:12347
ICD1030 Q78.0
ICD9CM32 756.51
MeSH39 D010013
Orphanet54 ORPHA666
MESH via Orphanet40 D010013
ICD10 via Orphanet31 Q78.0
UMLS via Orphanet69 C0029434

Summaries for Osteogenesis Imperfecta

About this section
MedlinePlus:38 Osteogenesis imperfecta (oi) is a genetic disorder in which bones break easily. sometimes the bones break for no known reason. oi can also cause weak muscles, brittle teeth, a curved spine, and hearing loss. oi is caused by one of several genes that aren't working properly. when these genes don't work, it affects how you make collagen, a protein that helps make bones strong. oi can range from mild to severe, and symptoms vary from person to person. a person may have just a few or as many as several hundred fractures in a lifetime. no single test can identify oi. your doctor uses your medical and family history, physical exam, and imaging and lab tests to diagnose it. your doctor may also test your collagen (from skin) or genes (from blood). there is no cure, but you can manage symptoms. treatments include exercise, pain medicine, physical therapy, wheelchairs, braces, and surgery. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary: Osteogenesis Imperfecta, also known as brittle bone disease, is related to osteogenesis imperfecta, type iii and osteogenesis imperfecta, type ii, and has symptoms including back pain, back pain and muscle cramp. An important gene associated with Osteogenesis Imperfecta is COL1A2 (Collagen Type I Alpha 2 Chain), and among its related pathways are Osteoblast Signaling and Cell adhesion_ECM remodeling. The drugs calcitonin and salmon calcitonin have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and testes, and related mouse phenotypes are muscle and craniofacial.

NIH Rare Diseases:48 Osteogenesis imperfecta (oi) is a group of genetic disorders that mainly affect the bones. people with this condition have bones that break easily, often from little or no trauma. severity varies among affected people. multiple fractures are common, and in severe cases, can even occur before birth. milder cases may involve only a few fractures over a person's lifetime. people with oi also have dental problems (dentinogenesis imperfecta) and hearing loss in adulthood. other features may include muscle weakness, loose joints, and skeletal malformations. there are various recognized forms of oi which are distinguished by their features and genetic causes. depending on the genetic cause, oi may be inherited in an autosomal dominant (more commonly) or autosomal recessive manner. treatment is supportive and aims to decrease the number of fractures and disabilities. last updated: 10/6/2015

Genetics Home Reference:25 Osteogenesis imperfecta (OI) is a group of genetic disorders that mainly affect the bones. The term "osteogenesis imperfecta" means imperfect bone formation. People with this condition have bones that break easily, often from mild trauma or with no apparent cause. Multiple fractures are common, and in severe cases, can occur even before birth. Milder cases may involve only a few fractures over a person's lifetime.

Disease Ontology:11 An osteochondrodysplasia that has material basis in a deficiency in type-I collagen which results in brittle bones and defective connective tissue.

Wikipedia:71 Osteogenesis imperfecta (OI), also known as brittle bone disease, is a group of genetic disorders that... more...

Related Diseases for Osteogenesis Imperfecta

About this section

Diseases in the Osteogenesis Imperfecta family:

Osteogenesis Imperfecta, Type Viii Osteogenesis Imperfecta, Type Vii
Osteogenesis Imperfecta, Type Xvii Osteogenesis Imperfecta, Type Iv
Osteogenesis Imperfecta, Type Iii Osteogenesis Imperfecta, Type Ii
Osteogenesis Imperfecta, Type Xiii Osteogenesis Imperfecta, Type Xiv
Osteogenesis Imperfecta, Type V Osteogenesis Imperfecta, Type Xvi
Osteogenesis Imperfecta, Type X Osteogenesis Imperfecta, Type Xv
Osteogenesis Imperfecta, Type Xii Osteogenesis Imperfecta, Type Ix
Osteogenesis Imperfecta, Type Vi Osteogenesis Imperfecta, Type Xi
Osteogenesis Imperfecta, Type I Bmp1-Related Osteogenesis Imperfecta
Crtap-Related Osteogenesis Imperfecta Fkbp10-Related Osteogenesis Imperfecta
Ifitm5-Related Osteogenesis Imperfecta P3h1-Related Osteogenesis Imperfecta
Ppib-Related Osteogenesis Imperfecta Serpinf1-Related Osteogenesis Imperfecta
Serpinh1-Related Osteogenesis Imperfecta Sp7-Related Osteogenesis Imperfecta
Tmem38b-Related Osteogenesis Imperfecta Sparc-Related Osteogenesis Imperfecta
Wnt1-Related Osteogenesis Imperfecta

Diseases related to Osteogenesis Imperfecta via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 212)
idRelated DiseaseScoreTop Affiliating Genes
1osteogenesis imperfecta, type iii34.3COL1A1, COL1A2
2osteogenesis imperfecta, type ii32.7CD36, COL1A1, COL1A2, CRTAP, DSPP, FKBP10
3osteogenesis imperfecta, type i12.7
4osteogenesis imperfecta, type vi12.6
5osteogenesis imperfecta, type iv12.6
6osteogenesis imperfecta, type vii12.6
7osteogenesis imperfecta, type v12.6
8osteogenesis imperfecta, type viii12.6
9osteogenesis imperfecta, type ix12.5
10osteogenesis imperfecta, type xi12.5
11osteogenesis imperfecta, type xiv12.5
12osteogenesis imperfecta, type xv12.5
13osteogenesis imperfecta, type x12.5
14osteogenesis imperfecta, type xii12.5
15osteogenesis imperfecta, type xiii12.5
16osteogenesis imperfecta, type xvi12.4
17osteogenesis imperfecta, type xvii12.4
18osteogenesis imperfecta with opalescent teeth, blue sclerae and wormian bones but without fractures12.2
19high bone mass osteogenesis imperfecta12.1
20perinatally lethal osteogenesis imperfecta12.1
21progressively deforming osteogenesis imperfecta12.1
22col1a1/2-related osteogenesis imperfecta12.1
23osteogenesis imperfecta congenita, microcephaly, and cataracts12.1
24bruck syndrome12.0
25osteogenesis imperfecta levin type12.0
26common variable osteogenesis imperfecta with normal sclerae12.0
27wnt1-related osteogenesis imperfecta12.0
28tmem38b-related osteogenesis imperfecta11.9
29classic non-deforming osteogenesis imperfecta with blue sclerae11.9
30sparc-related osteogenesis imperfecta11.9
31dentinogenesis imperfecta11.9
32bmp1-related osteogenesis imperfecta11.9
33crtap-related osteogenesis imperfecta11.9
34fkbp10-related osteogenesis imperfecta11.9
35ifitm5-related osteogenesis imperfecta11.9
36p3h1-related osteogenesis imperfecta11.9
37ppib-related osteogenesis imperfecta11.9
38serpinf1-related osteogenesis imperfecta11.9
39serpinh1-related osteogenesis imperfecta11.9
40sp7-related osteogenesis imperfecta11.9
41osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome11.9
42ehlers-danlos/osteogenesis imperfecta syndrome11.9
43dentinogenesis imperfecta, shields type ii11.7
44osteoporosis-pseudoglioma syndrome11.6
45bruck syndrome 211.5
46cole-carpenter syndrome11.4
47gnathodiaphyseal dysplasia11.2
48dentinogenesis imperfecta, shields type iii10.9
49cole-carpenter syndrome 210.9
50cole-carpenter syndrome 110.9

Graphical network of the top 20 diseases related to Osteogenesis Imperfecta:



Diseases related to osteogenesis imperfecta

Symptoms & Phenotypes for Osteogenesis Imperfecta

About this section

Human phenotypes related to Osteogenesis Imperfecta:

 54 64 (show all 54)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 inguinal hernia64 54 Occasional (29-5%) HP:0000023
2 abnormality of the teeth54 Very frequent (99-80%)
3 large fontanelles64 54 Frequent (79-30%) HP:0000239
4 brachycephaly64 54 Very frequent (99-80%) HP:0000248
5 macrocephaly64 54 Very frequent (99-80%) HP:0000256
6 prominent occiput64 54 Very frequent (99-80%) HP:0000269
7 triangular face64 54 Frequent (79-30%) HP:0000325
8 micrognathia64 54 Very frequent (99-80%) HP:0000347
9 hearing impairment64 54 Occasional (29-5%) HP:0000365
10 convex nasal ridge64 54 Very frequent (99-80%) HP:0000444
11 glaucoma64 54 Frequent (79-30%) HP:0000501
12 visual impairment64 54 Frequent (79-30%) HP:0000505
13 blue sclerae64 54 Very frequent (99-80%) HP:0000592
14 carious teeth64 54 Very frequent (99-80%) HP:0000670
15 abnormality of dental enamel64 54 Very frequent (99-80%) HP:0000682
16 dentinogenesis imperfecta64 54 Very frequent (99-80%) HP:0000703
17 pectus excavatum64 54 Occasional (29-5%) HP:0000767
18 pectus carinatum64 54 Very frequent (99-80%) HP:0000768
19 abnormality of the ribs54 Very frequent (99-80%)
20 narrow chest64 54 Frequent (79-30%) HP:0000774
21 thin ribs64 54 Very frequent (99-80%) HP:0000883
22 osteopenia64 54 Frequent (79-30%) HP:0000938
23 osteoporosis64 54 Frequent (79-30%) HP:0000939
24 abnormality of the metaphyses64 54 Very frequent (99-80%) HP:0000944
25 hyperhidrosis64 54 Frequent (79-30%) HP:0000975
26 gait disturbance64 54 Very frequent (99-80%) HP:0001288
27 intrauterine growth retardation64 54 Very frequent (99-80%) HP:0001511
28 umbilical hernia64 54 Occasional (29-5%) HP:0001537
29 thrombocytopenia64 54 Occasional (29-5%) HP:0001873
30 malformation of the heart and great vessels54 Frequent (79-30%)
31 wormian bones64 54 Occasional (29-5%) HP:0002645
32 scoliosis64 54 Frequent (79-30%) HP:0002650
33 recurrent fractures64 54 Occasional (29-5%) HP:0002757
34 kyphosis64 54 Occasional (29-5%) HP:0002808
35 abnormality of the femur54 Frequent (79-30%)
36 genu valgum64 54 Frequent (79-30%) HP:0002857
37 femoral bowing64 54 Frequent (79-30%) HP:0002980
38 micromelia64 54 Occasional (29-5%) HP:0002983
39 abnormality of the tibia64 54 Very frequent (99-80%) HP:0002992
40 slender long bone64 54 Frequent (79-30%) HP:0003100
41 abnormal cortical bone morphology64 54 Frequent (79-30%) HP:0003103
42 protrusio acetabuli64 54 Frequent (79-30%) HP:0003179
43 abnormality of the hip bone54 Frequent (79-30%)
44 abnormal form of the vertebral bodies54 Frequent (79-30%)
45 abnormality of the endocardium64 54 Occasional (29-5%) HP:0004306
46 short stature64 54 Occasional (29-5%) HP:0004322
47 decreased skull ossification64 54 Very frequent (99-80%) HP:0004331
48 biconcave vertebral bodies64 54 Frequent (79-30%) HP:0004586
49 diaphyseal thickening64 54 Very frequent (99-80%) HP:0005019
50 joint hyperflexibility64 54 Frequent (79-30%) HP:0005692
51 bowing of the long bones54 Frequent (79-30%)
52 corneal opacity64 54 Frequent (79-30%) HP:0007957
53 abnormality of dental color64 54 Very frequent (99-80%) HP:0011073
54 visceral angiomatosis64 54 Occasional (29-5%) HP:0100761

UMLS symptoms related to Osteogenesis Imperfecta:


back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Osteogenesis Imperfecta according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053698.8BMP1, CD36, COL1A1, COL1A2, P3H1, PEPD
2MP:00053828.5BMP1, COL1A1, FGFR3, FKBP10, IFITM5, PPIB
3MP:00053858.4BMP1, CD36, COL1A1, COL1A2, FKBP10, PEPD
4MP:00053717.8BMP1, COL1A1, COL1A2, FGFR3, FKBP10, IFITM5
5MP:00053787.6BMP1, CD36, COL1A1, COL1A2, CRTAP, FGFR3
6MP:00107686.7BMP1, CD36, COL1A1, COL1A2, FGFR3, FKBP10
7MP:00053905.9BMP1, CD36, COL1A1, COL1A2, CRTAP, FGFR3

Drugs & Therapeutics for Osteogenesis Imperfecta

About this section

Drugs for Osteogenesis Imperfecta (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
PamidronateapprovedPhase 4, Phase 3, Phase 24440391-99-94674
Synonyms:
(3-AMINO-1-HYDROXY-1-PHOSPHONO-PROPYL)PHOSPHONIC ACID
(3-Amino-1-hydroxypropylidene)bisphosphonic acid
(3-Amino-1-hydroxypropylidene)diphosphonic acid
(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)
(3-amino-1-hydroxypropylidene)-1,1-biphosphonate
(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate
1-hydroxy-3-aminopropane-1,1-diphosphonic acid
3-Amino-1-hydroxypropylidene-1,1-diphosphonate
40391-99-9
57248-88-1
57248-88-1 (di-hydrochloride salt)
AC1L1IP4
AHPrBP
AKOS003599275
APD
Acide pamidronique
Acide pamidronique [INN-French]
Acido pamidronico
Acido pamidronico [INN-Spanish]
Acidum pamidronicum
Acidum pamidronicum [INN-Latin]
Amidronate
Aminomux
Aredia
BIDD:GT0538
Bisphosphonate 6
C019248
C07395
C3H11NO7P2
 
CHEMBL834
CID4674
ChemDiv1_025240
D07281
DB00282
EINECS 254-905-2
HMS2090C13
HMS658L06
HSCI1_000312
I14-2407
LS-174826
MolPort-002-131-054
NCGC00159433-02
NCGC00159433-03
Novartis brand of pamidronate disodium salt
PAMIDRONATE DISODIUM
PAMIDRONIC ACID
Pamidronate Disodium
Pamidronic acid
Pamidronic acid (INN)
Pamidronic acid [INN:BAN]
Ribodroat
Ribodroat (TN)
STOCK1N-12562
UNII-OYY3447OMC
amino-1-hydroxypropane-1,1-diphosphonate
aminohydroxypropylidene diphosphonate
aminopropanehydroxydiphosphonate
pamidronate
pamidronate calcium
pamidronate monosodium
2
AlendronateapprovedPhase 4162121268-17-5, 66376-36-12088
Synonyms:
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-hydroxybutylidene)bisphosphonic acid
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
4-amino-1-hydroxybutane-1,1-diphosphonic acid
66376-36-1
ABDP
AC1L1CW3
AKOS001015793
ALENDRONATE SODIUM
ALENDRONIC ACID
Acide Alendronique
Acide Alendronique [INN-French]
Acide alendronique
Acide alendronique [INN-French]
Acido Alendronico
Acido Alendronico [INN-Spanish]
Acido alendronico
Acido alendronico [INN-Spanish]
Acidum Alendronicum
Acidum Alendronicum [INN-Latin]
Acidum alendronicum
Acidum alendronicum [INN-Latin]
Adronat
 
Alendronate
Alendronate Sodium
Alendronate sodium hydrate
Alendronic acid
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Arendal
BIDD:GT0180
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
alendronate
bisphosphonate, 65
3
Teriparatideapproved, investigationalPhase 4, Phase 213752232-67-416133850
Synonyms:
52232-67-4
D06078
Forteo
Forteo (TN)
 
TERIPARATIDE
Teriparatide (USAN/INN)
Teriparatide (genetical recombination)
Teriparatide (genetical recombination) (JAN)
Teriparatide recombinant human
4
Ergocalciferolapproved, nutraceuticalPhase 4128150-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
5
Cholecalciferolapproved, nutraceuticalPhase 487567-97-06221, 10883523, 5280795
Synonyms:
()-Vitamin D3
(+)-Vitamin D3
(+)-vitamin D3
(1S,3Z)-3-[(2e)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol
47763_SUPELCO
57651-82-8
67-97-0
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
9,10-Secocholesta-5,7,10(19)-trien-3-ol
9,10-Secocholesta-5,7,10-trien-3-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
Activated 7-dehydrocholesterol
Arachitol
BPBio1_000460
BSPBio_000418
BSPBio_002408
Bio-0845
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
CID7067440
CID7251172
CID7251174
CID9821465
Calciol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol D3
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferolum
Colecalciferol
 
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Devaron
DivK1c_006276
Duphafral D3 1000
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
Ebivit
FeraCol
Granuvit D3
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC-375571
NSC375571
Oleovitamin D3
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Prestwick_63
Provitamine
Provitina
Quintox
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SR-05000001559
SR-05000001559-3
ST057172
SpecPlus_000180
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
Spectrum_001163
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
VITAMIN D
VITAMIN D3 POWDER
VITAMIN_D3
Vi-De3
Vi-de-3-hydrosol
VidDe-3-hydrosol
Videkhol
Vigantol
Vigorsan
Vitamin D-3
Vitamin D3
Vitamin D3 emulsifiable
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
bmse000507
cholecalciferol
colecalciferolum
vitamin d-3
6VitaminsPhase 4, Phase 25282
7Bone Density Conservation AgentsPhase 4, Phase 3, Phase 23376
8vitamin dPhase 4, Phase 21724
9DiphosphonatesPhase 4, Phase 3, Phase 2450
10MicronutrientsPhase 46001
11ErgocalciferolsPhase 41281
12Trace ElementsPhase 46001
13CalciferolNutraceuticalPhase 41383
14Vitamin D2NutraceuticalPhase 41281
15
Zoledronic acidapprovedPhase 3, Phase 2294118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
 
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
16
DenosumabapprovedPhase 3, Phase 2138615258-40-7
Synonyms:
615258-40-7
AMG-162
D03684
Denosumab
 
Denosumab (USAN)
Denosumab (genetical recombination)
Denosumab (genetical recombination) (JAN)
Prolia
Xgeva
17
Etidronic acidapprovedPhase 3827414-83-7, 2809-21-43305
Synonyms:
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphoshonic acid
(1-Hydroxyethylidene)diphosphonic acid
(1-hydroxy-1-phosphonoethyl)phosphonic acid
(1-hydroxy-ethylidene)diphosphonic acid
(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)
(Hydroxyethylidene)diphosphonic acid
0-02-00-00171 (Beilstein Handbook Reference)
1,1,1-Ethanetriol diphosphonate
1-HYDROXY-1,1-DIPHOSPHONOETHANE
1-Hydroxy-1,1-diphosphonoethane
1-Hydroxyethane-1,1,-diphosphonic acid
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylidene 1,1-diphosphonic acid
1-Hydroxyethylidene-1,1-biphosphonate
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
1-Hydroxyethylidenediphosphonic acid
1-hydroxyethane 1,1-diphosphonic acid
1000SL
100511-44-2
103736-66-9
106908-76-3
129130-42-3
138360-84-6
14860-53-8 (tetra-potassium salt)
192526-55-9
2809-21-4
303177-33-5
51888-66-5
54342_ALDRICH
54342_FLUKA
66216-98-6
853028-38-3
85985-26-8
86159-18-4
AC1L1FMT
Acetodiphosphonic acid
Acide etidronique
Acide etidronique [INN-French]
Acido etidronico
Acido etidronico [INN-Spanish]
Acidum etidronicum
Acidum etidronicum [INN-Latin]
BPBio1_000997
BRN 1789291
BSPBio_000905
Bio-0708
C07736
CHEBI:170675
CHEBI:4907
CHEMBL871
CID3305
 
Cintichem Technetium 99m Hedspa
D02373
DB01077
Dequest 2010
Dequest 2015
Dequest Z 010
Didronel
Didronel IV
Diphosphonate (base)
EHDP
EINECS 220-552-8
Ethane-1-hydroxy-1,1-bisphosphonate
Ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Etidronate
Etidronate Disodium
Etidronic acid
Etidronic acid (USAN/INN)
Etidronic acid [USAN:INN:BAN]
Etidronic acid monohydrate
Etidronsaeure
Etidronsäure
Ferrofos 510
H0587
H6773_ALDRICH
H6773_SIGMA
HEDP
HSDB 5898
Hydroxyethane-1,1-diphosphonic acid
Hydroxyethanediphosphonic acid
I14-1271
Jsp005415
LS-106637
MLS002207267
MLS002695948
MPI Stannous Diphosphonate
MolPort-001-786-542
NCGC00159352-02
NSC 227995
NSC227995
Osteoscan
Oxyethylidenediphosphonic acid
Phosphonic acid, 1-hydroxy-1,1-ethanediyl ester
Prestwick0_000863
Prestwick1_000863
Prestwick2_000863
Prestwick3_000863
RP 61
SMR000038750
SPBio_002826
STK721995
Turpinal SL
UNII-M2F465ROXU
acide étidronique
acidum etidronicum
ethane-1-hydroxy-1,1-bisphosphonic acid
etidronate
ácido etidrónico
18Risedronate SodiumPhase 398115436-72-1
19HormonesPhase 314415
20Hormone AntagonistsPhase 313180
21Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 313168
22calcium channel blockersPhase 31985
23Calcium, DietaryPhase 3, Phase 25713
24ImmunoglobulinsPhase 2, Phase 16394
25AntibodiesPhase 2, Phase 16394
26
Cyclophosphamideapproved, investigationalPhase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
27
Cyclosporineapproved, investigational, vet_approvedPhase 192279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
28
Busulfanapproved, investigationalPhase 154555-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
29
Miconazoleapproved, investigational, vet_approvedPhase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
30Dermatologic AgentsPhase 15806
31Immunosuppressive AgentsPhase 113086
32Alkylating AgentsPhase 14827
33Antirheumatic AgentsPhase 110956
34Antifungal AgentsPhase 13696
35Antineoplastic Agents, AlkylatingPhase 14603
36Calcineurin InhibitorsPhase 11622
37Anti-Infective AgentsPhase 122062
38Antibodies, MonoclonalPhase 14039
39
Mentholapproved26062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
40Antidepressive Agents2736
41Lithium carbonate240554-13-2
42Tranquilizing Agents4265
43Central Nervous System Depressants13403
44Antimanic Agents814
45Psychotropic Drugs6430
46Hydroxycholecalciferols129
47Anabolic Agents513
48
Citric Acidnutraceutical, vet_approved116077-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
49CitrateNutraceutical1160

Interventional clinical trials:

(show all 37)
idNameStatusNCT IDPhase
1Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis ImperfectaCompletedNCT00131469Phase 4
2Effect of High-Dose Vitamin D on Bone Density in Osteogenesis ImperfectaCompletedNCT01713231Phase 4
3Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis ImperfectaCompletedNCT02303873Phase 4
4Bisphosphonate Therapy for Osteogenesis ImperfectaCompletedNCT00159419Phase 4
5Growth Hormone Therapy in Osteogenesis ImperfectaCompletedNCT00001305Phase 3
6Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in ChildrenCompletedNCT00106028Phase 3
7An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis ImperfectaCompletedNCT00982124Phase 3
8Pamidronate to Treat Osteogenesis Imperfecta in ChildrenCompletedNCT00005901Phase 3
9Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OIRecruitingNCT02352753Phase 3
10Bisphosphonate Treatment of Osteogenesis ImperfectaCompletedNCT00063479Phase 2
11Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis ImperfectaCompletedNCT01417091Phase 2
12Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis ImperfectaCompletedNCT00131118Phase 2
13Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody DenosumabCompletedNCT01799798Phase 2
14Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TICompletedNCT01140321Phase 2
15The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis ImperfectaRecruitingNCT01679080Phase 2
16A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804RecruitingNCT03118570Phase 2
17Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis ImperfectaCompletedNCT01061099Phase 1
18Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow TransplantationCompletedNCT00705120Phase 1
19Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow TransplantationCompletedNCT00186914Phase 1
20Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis ImperfectaActive, not recruitingNCT02172885Phase 1
21Safety of Fresolimumab in the Treatment of Osteogenesis ImperfectaNot yet recruitingNCT03064074Phase 1
22Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot StudyCompletedNCT00187018
23Osteogenesis Imperfecta (OI) Quality of Life Survey Pilot Project 2CompletedNCT02793063
24Whole Body Vibration Training in Children With Osteogenesis Imperfecta and Limited MobilityCompletedNCT03029312
25The Influence of Bisphosphonates in the Oral Cavity in ChildrenCompletedNCT00402064
26Prevention of Post Operative Bone Loss in ChildrenCompletedNCT00655681
27Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma SyndromeCompletedNCT01108068
28Evaluation and Intervention for the Effects of Osteogenesis ImperfectaRecruitingNCT00001594
29BBD Longitudinal Study of Osteogenesis ImperfectaRecruitingNCT02432625
30Preventive Fixation of Lower Limbs in Osteogenesis Imperfecta (Brittle Bone Disease) With the Highlight of the Fassier-DuvalRecruitingNCT02868294
31Urinary Biomarkers of OI PathobiologyRecruitingNCT02531087
32Dental Malocclusion and Craniofacial Development in OIRecruitingNCT02934451
33Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman SpectroscopyEnrolling by invitationNCT02814591
34Pregnancy in Osteogenesis Imperfecta (OI) RegistryNot yet recruitingNCT03072303
35Diagnosis of Osteogenesis Imperfecta in ChildrenNot yet recruitingNCT03169192
36Effects of a Physical Rehabilitation Program Using the Nintendo Wii on Children With Osteogenesis Imperfecta (OI)TerminatedNCT02542540
37Growth Hormone for Osteoporosis Pseudoglioma SyndromeWithdrawnNCT01614171

Search NIH Clinical Center for Osteogenesis Imperfecta

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: osteogenesis imperfecta

Genetic Tests for Osteogenesis Imperfecta

About this section

Genetic tests related to Osteogenesis Imperfecta:

id Genetic test Affiliating Genes
1 Osteogenesis Imperfecta27 24

Anatomical Context for Osteogenesis Imperfecta

About this section

MalaCards organs/tissues related to Osteogenesis Imperfecta:

36
Bone, Skin, Testes, Eye, Bone marrow, Heart, Breast

Publications for Osteogenesis Imperfecta

About this section

Articles related to Osteogenesis Imperfecta:

(show top 50)    (show all 1028)
idTitleAuthorsYear
1
Novel missense loss-of-function mutations of WNT1 in an autosomal recessive Osteogenesis imperfecta patient. (28528193)
2017
2
The effect of whole body vibration training on bone and muscle function in children with osteogenesis imperfecta. (28472303)
2017
3
Letter to the Editor: Therapies for Osteogenesis Imperfecta. (28527487)
2017
4
WHOLE-BODY VIBRATION EXERCISE IMPROVES FUNCTIONAL PARAMETERS IN PATIENTS WITH OSTEOGENESIS IMPERFECTA: A SYSTEMATIC REVIEW WITH A SUITABLE APPROACH. (28480432)
2017
5
Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. (28435282)
2017
6
Osteogenesis imperfecta type 3 in South Africa: Causative mutations in FKBP10. (28492130)
2017
7
Developmental charts for children with osteogenesis imperfecta, type I (body height, body weight and BMI). (28058531)
2017
8
The Spine in Patients With Osteogenesis Imperfecta. (28009707)
2017
9
Clinical application of quantitative computed tomography in osteogenesis imperfecta suspected cat. (28057908)
2017
10
Gene expression profiling of bone marrow mesenchymal stem cells from Osteogenesis Imperfecta patients during osteoblast differentiation. (28396251)
2017
11
SURGICAL MANAGEMENT OF RETINAL DETACHMENT IN OSTEOGENESIS IMPERFECTA: CASE REPORT AND REVIEW OF THE LITERATURE. (28085759)
2017
12
Isolated olecranon fractures in children affected by osteogenesis imperfecta type I treated with single screw or tension band wiring system: Outcomes and pitfalls in relation to bone mineral density. (28514292)
2017
13
Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta. (28461254)
2017
14
Femoral and Lumbar Fractures During Rehabilitation for a Traumatic Spinal Cord Injury in Osteogenesis Imperfecta: A Case Presentation. (28483687)
2017
15
The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model for dominant osteogenesis imperfecta. (28475764)
2017
16
Corrigendum] Clinical characteristics and the identification of novel mutations of COL1A1 and COL1A2 in 61A Chinese patients with osteogenesis imperfecta. (28035422)
2017
17
Static postural control in youth with osteogenesis imperfecta type I. (28433416)
2017
18
Compound heterozygous mutations in COL1A1 associated with an atypical form of type I osteogenesis imperfecta. (28436160)
2017
19
A Rare Case of Bilateral Morgagni's Hernia with Intestinal Obstruction and Malrotation of the Gut in an Adult Patient with Severe Osteogenesis Imperfecta Presenting as Severe Respiratory Distress. (28442844)
2017
20
Molecular diagnosis in children with fractures but no extraskeletal signs of osteogenesis imperfecta. (28378289)
2017
21
Muscle Function in Osteogenesis Imperfecta Type IV. (28474170)
2017
22
Progressive Bilateral Vertebral Artery Dissection in a Case of Osteogenesis Imperfecta. (28089253)
2017
23
Next-Generation Sequencing Reveals One Novel Missense Mutation in COL1A2 Gene in an Iranian Family with Osteogenesis imperfecta (28431466)
2017
24
Mutations in COL1A1 and COL1A2 and dental aberrations in children and adolescents with osteogenesis imperfecta - A retrospective cohort study. (28498836)
2017
25
Targeted exome sequencing identifies novel compound heterozygous mutations in P3H1 in a fetus with osteogenesis imperfecta type VIII. (27864101)
2017
26
Combined Spinal-Epidural Anesthesia With Dexmedetomidine-Based Sedation for Multiple Corrective Osteotomies in a Child With Osteogenesis Imperfecta Type III: A Case Report. (28448325)
2017
27
Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta. (28528406)
2017
28
Rare co-occurrence of osteogenesis imperfecta type I and autosomal dominant polycystic kidney disease. (27059743)
2016
29
Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment. (26954289)
2016
30
Diagnostic conundrums in antenatal presentation of a skeletal dysplasia with description of a heterozygous C-propeptide mutation in COL1A1 associated with a severe presentation of osteogenesis imperfecta. (27549894)
2016
31
DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum. (27509835)
2016
32
Bone Material Properties in Osteogenesis Imperfecta. (26987995)
2016
33
Pigment epithelium-derived factor (PEDF) normalizes matrix defects in iPSCs derived from Osteogenesis imperfecta Type VI. (27579219)
2016
34
Analysis of COL1A1 gene mutation in an ethnic Han Chinese family from Henan affected with osteogenesis imperfecta]. (27577215)
2016
35
Craniofacial and Dental Defects in the Col1a1Jrt/+ Mouse Model of Osteogenesis Imperfecta. (26951553)
2016
36
Urinary Cross-linked N-terminal Telopeptide of Type I Collagen Levels of Infants with Osteogenesis Imperfecta and Healthy Infants. (28003667)
2016
37
Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations - genotype-phenotype correlations and effect of bisphosphonate treatment. (26927310)
2016
38
Bilateral papilledema in a child with osteogenesis imperfecta. (27833926)
2016
39
Mutants of collagen-specific molecular chaperone Hsp47 causing osteogenesis imperfecta are structurally unstable with weak binding affinity to collagen. (26692483)
2016
40
Osteogenesis imperfecta: Level of independence and of social, recreational and sports participation among adolescents and youth. (27164338)
2016
41
Ultrasonographic early diagnosis of osteogenesis imperfecta type I: implications for pre and post-natal therapy. (27052443)
2016
42
Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta. (27821779)
2016
43
Osteogenesis Imperfecta Diagnosed from Mandibular and Lower Limb Fractures: A Case Report. (27162570)
2016
44
Worsening of Callus Hyperplasia after Bisphosphonate Treatment in Type V Osteogenesis Imperfecta. (27029692)
2016
45
Premature Atherosclerosis and Drug Eluting Stent Restenosis in an Adult with Osteogenesis Imperfecta. (28031688)
2016
46
Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. (26957348)
2016
47
Children with severe Osteogenesis imperfecta and short stature present on average with normal IGF-I and IGFBP-3 levels. (27089405)
2016
48
Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. (27894323)
2016
49
Analysis of gross deletions of COL1A1/2 genes in Chinese families affected with osteogenesis imperfecta]. (27454992)
2016
50
Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial. (26944820)
2016

Variations for Osteogenesis Imperfecta

About this section

Clinvar genetic disease variations for Osteogenesis Imperfecta:

5 (show all 35)
id Gene Variation Type Significance SNP ID Assembly Location
1COL1A1NM_ 000088.3(COL1A1): c.994G> A (p.Gly332Arg)SNVPathogenicrs72645357GRCh37Chr 17, 48273524: 48273524
2COL1A1NM_ 000088.3(COL1A1): c.787G> A (p.Gly263Arg)SNVPathogenicrs72645323GRCh37Chr 17, 48274388: 48274388
3COL1A1NM_ 000088.3(COL1A1): c.1021G> T (p.Gly341Cys)SNVLikely pathogenicrs193922137GRCh37Chr 17, 48273319: 48273319
4COL1A1NM_ 000088.3(COL1A1): c.1200+1G> ASNVPathogenicrs72648320GRCh37Chr 17, 48272794: 48272794
5COL1A1NM_ 000088.3(COL1A1): c.1235C> G (p.Pro412Arg)SNVLikely pathogenicrs193922138GRCh37Chr 17, 48272657: 48272657
6COL1A1NM_ 000088.3(COL1A1): c.1544G> C (p.Gly515Ala)SNVLikely pathogenicrs193922140GRCh37Chr 17, 48271780: 48271780
7COL1A1NM_ 000088.3(COL1A1): c.1583G> A (p.Arg528His)SNVLikely pathogenicrs144751329GRCh37Chr 17, 48271741: 48271741
8COL1A1NM_ 000088.3(COL1A1): c.1657delA (p.Thr553Leufs)deletionLikely pathogenicrs193922141GRCh37Chr 17, 48271502: 48271502
9COL1A1NM_ 000088.3(COL1A1): c.1812delT (p.Gly605Alafs)deletionLikely pathogenicrs193922143GRCh37Chr 17, 48270364: 48270364
10COL1A1NM_ 000088.3(COL1A1): c.2062C> T (p.Gln688Ter)SNVLikely pathogenicrs193922144GRCh37Chr 17, 48269214: 48269214
11COL1A1NM_ 000088.3(COL1A1): c.2161C> T (p.Gln721Ter)SNVPathogenic/ Likely pathogenicrs193922145GRCh37Chr 17, 48268818: 48268818
12COL1A1NM_ 000088.3(COL1A1): c.2398-1G> CSNVLikely pathogenicrs193922147GRCh37Chr 17, 48267742: 48267742
13COL1A1NM_ 000088.3(COL1A1): c.2418delT (p.Gly809Alafs)deletionLikely pathogenicrs193922148GRCh37Chr 17, 48267721: 48267721
14COL1A1NM_ 000088.3(COL1A1): c.2450delC (p.Pro817Leufs)deletionLikely pathogenicrs193922149GRCh37Chr 17, 48267689: 48267689
15COL1A1NM_ 000088.3(COL1A1): c.2594G> A (p.Arg865His)SNVLikely pathogenicrs193922150GRCh37Chr 17, 48267239: 48267239
16COL1A1NM_ 000088.3(COL1A1): c.2685delT (p.Gly896Alafs)deletionLikely pathogenicrs193922151GRCh37Chr 17, 48266882: 48266882
17COL1A1NM_ 000088.3(COL1A1): c.2897A> G (p.Gln966Arg)SNVLikely pathogenicrs193922152GRCh37Chr 17, 48266569: 48266569
18COL1A1NM_ 000088.3(COL1A1): c.2932C> T (p.Pro978Ser)SNVLikely pathogenicrs193922153GRCh37Chr 17, 48266534: 48266534
19COL1A1NM_ 000088.3(COL1A1): c.299_ 300delAG (p.Glu100Valfs)deletionLikely pathogenicrs193922154GRCh37Chr 17, 48276950: 48276951
20COL1A1NM_ 000088.3(COL1A1): c.3076C> T (p.Arg1026Ter)SNVPathogenicrs72653173GRCh37Chr 17, 48266126: 48266126
21COL1A1NM_ 000088.3(COL1A1): c.370-2A> GSNVLikely pathogenicrs193922155GRCh37Chr 17, 48276690: 48276690
22COL1A1NM_ 000088.3(COL1A1): c.517G> T (p.Gly173Ter)SNVLikely pathogenicrs193922157GRCh37Chr 17, 48275820: 48275820
23COL1A1NM_ 000088.3(COL1A1): c.579delT (p.Gly194Valfs)deletionLikely pathogenicrs72667023GRCh37Chr 17, 48275531: 48275531
24COL1A1NM_ 000088.3(COL1A1): c.751-2A> GSNVLikely pathogenicrs193922158GRCh37Chr 17, 48274426: 48274426
25COL1A1NM_ 000088.3(COL1A1): c.805G> A (p.Gly269Ser)SNVLikely pathogenicrs72645328GRCh37Chr 17, 48274031: 48274031
26COL1A2NM_ 000089.3(COL1A2): c.1148C> A (p.Pro383His)SNVLikely pathogenicrs193922159GRCh37Chr 7, 94039790: 94039790
27COL1A2NM_ 000089.3(COL1A2): c.1873G> A (p.Gly625Ser)SNVLikely pathogenicrs193922162GRCh37Chr 7, 94047045: 94047045
28COL1A2NM_ 000089.3(COL1A2): c.1991G> A (p.Gly664Asp)SNVLikely pathogenicrs72658154GRCh37Chr 7, 94047830: 94047830
29COL1A2NM_ 000089.3(COL1A2): c.2827G> A (p.Gly943Arg)SNVLikely pathogenicrs193922165GRCh37Chr 7, 94054967: 94054967
30COL1A2NM_ 000089.3(COL1A2): c.3106-2delAdeletionLikely pathogenicrs193922166GRCh37Chr 7, 94056318: 94056318
31COL1A2NM_ 000089.3(COL1A2): c.3284delC (p.Pro1095Leufs)deletionLikely pathogenicrs193922167GRCh37Chr 7, 94056955: 94056955
32COL1A2NM_ 000089.3(COL1A2): c.3355G> C (p.Ala1119Pro)SNVLikely pathogenicrs193922168GRCh37Chr 7, 94057026: 94057026
33COL1A2NM_ 000089.3(COL1A2): c.677G> A (p.Gly226Asp)SNVLikely pathogenicrs193922173GRCh37Chr 7, 94037532: 94037532
34COL1A2NM_ 000089.3(COL1A2): c.838G> A (p.Gly280Ser)SNVPathogenicrs72656387GRCh37Chr 7, 94038679: 94038679
35COL1A2NM_ 000089.3(COL1A2): c.848_ 850delGTG (p.Gly283del)deletionLikely pathogenicrs193922175GRCh37Chr 7, 94038689: 94038691

Expression for genes affiliated with Osteogenesis Imperfecta

About this section
Search GEO for disease gene expression data for Osteogenesis Imperfecta.

Pathways for genes affiliated with Osteogenesis Imperfecta

About this section

GO Terms for genes affiliated with Osteogenesis Imperfecta

About this section

Cellular components related to Osteogenesis Imperfecta according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1collagen type I trimerGO:000558410.9COL1A1, COL1A2
2platelet alpha granule membraneGO:003109210.5CD36, SPARC
3macromolecular complexGO:003299110.5CRTAP, P3H1, PPIB
4collagen trimerGO:000558110.2CD36, COL1A1, COL1A2, SERPINH1
5endoplasmic reticulum lumenGO:00057888.9BGLAP, COL1A1, COL1A2, CRTAP, FKBP10, P3H1
6proteinaceous extracellular matrixGO:00055788.5BMP1, COL1A1, COL1A2, CRTAP, DSPP, P3H1
7extracellular spaceGO:00056158.5BGLAP, BMP1, CD36, COL1A1, COL1A2, CRTAP
8extracellular regionGO:00055768.3BGLAP, BMP1, COL1A1, COL1A2, DSPP, FGFR3
9endoplasmic reticulumGO:00057837.5COL1A1, COL1A2, CRTAP, FGFR3, FKBP10, P3H1

Biological processes related to Osteogenesis Imperfecta according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of post-translational protein modificationGO:190187410.7CRTAP, P3H1
2protein heterotrimerizationGO:007020810.7COL1A1, COL1A2
3collagen biosynthetic processGO:003296410.7COL1A1, SERPINH1
4negative regulation of cell-substrate adhesionGO:001081210.6COL1A1, WNT1
5regulation of bone mineralizationGO:003050010.5BGLAP, IFITM5
6response to gravityGO:000962910.5BGLAP, SPARC
7collagen fibril organizationGO:003019910.5COL1A1, COL1A2, SERPINH1
8collagen catabolic processGO:003057410.4COL1A1, COL1A2, PEPD
9extracellular matrix organizationGO:003019810.1COL1A1, COL1A2, DSPP, SPARC
10skin morphogenesisGO:004358910.1COL1A1, COL1A2
11chaperone-mediated protein foldingGO:006107710.1CRTAP, FKBP10, P3H1, PPIB
12osteoblast differentiationGO:000164910.0BGLAP, COL1A1, SP7
13bone mineralizationGO:003028210.0BGLAP, FGFR3, IFITM5
14bone developmentGO:00603489.9BGLAP, P3H1, PPIB, SPARC, WNT1
15ossificationGO:00015039.7BGLAP, BMP1, COL1A1, DSPP, SPARC
16skeletal system developmentGO:00015018.8BGLAP, BMP1, COL1A1, COL1A2, DSPP, FGFR3

Molecular functions related to Osteogenesis Imperfecta according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular matrix structural constituentGO:000520110.2COL1A1, COL1A2, DSPP
2platelet-derived growth factor bindingGO:004840710.1COL1A1, COL1A2
3L-ascorbic acid bindingGO:00314189.7P3H1, PLOD2
4collagen bindingGO:00055189.7DSPP, P3H1, PPIB, SERPINH1, SPARC

Sources for Osteogenesis Imperfecta

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet